{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:35:45Z","timestamp":1793046945405,"version":"4.5.0"},"reference-count":183,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"DOI":"10.1038\/s41577-026-01348-5","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:21:06Z","timestamp":1787826066000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune-mediated excitotoxicity in brain disorders"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3556-125X","authenticated-orcid":false,"given":"Josef","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-7336","authenticated-orcid":false,"given":"Christina Francisca","family":"Vogelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2179-3655","authenticated-orcid":false,"given":"Stefan","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1231-1928","authenticated-orcid":false,"given":"Frauke","family":"Zipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"1348_CR1","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/S1474-4422(08)70165-0","volume":"7","author":"LV Kalia","year":"2008","unstructured":"Kalia, L. V., Kalia, S. K. & Salter, M. W. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol. 7, 742\u2013755 (2008).","journal-title":"Lancet Neurol."},{"key":"1348_CR2","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.immuni.2023.04.011","volume":"56","author":"F Zipp","year":"2023","unstructured":"Zipp, F., Bittner, S. & Schafer, D. P. Cytokines as emerging regulators of central nervous system synapses. Immunity 56, 914\u2013925 (2023).","journal-title":"Immunity"},{"key":"1348_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1515\/nf-2019-0009","volume":"25","author":"M Lenz","year":"2019","unstructured":"Lenz, M. & Vlachos, A. The neuroimmunological synapse: from synaptic homeostasis to brain disease. Neuroforum 25, 163\u2013171 (2019).","journal-title":"Neuroforum"},{"key":"1348_CR4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41577-021-00508-z","volume":"21","author":"AF Salvador","year":"2021","unstructured":"Salvador, A. F., de Lima, K. A. & Kipnis, J. Neuromodulation by the immune system: a focus on cytokines. Nat. Rev. Immunol. 21, 526\u2013541 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1348_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nrn3617","volume":"15","author":"DN Xanthos","year":"2014","unstructured":"Xanthos, D. N. & Sandk\u00fchler, J. Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. Nat. Rev. Neurosci. 15, 43\u201353 (2014).","journal-title":"Nat. Rev. Neurosci."},{"key":"1348_CR6","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1007\/s00018-018-2837-5","volume":"75","author":"B P\u00e1l","year":"2018","unstructured":"P\u00e1l, B. Involvement of extrasynaptic glutamate in physiological and pathophysiological changes of neuronal excitability. Cell. Mol. Life Sci. 75, 2917\u20132949 (2018).","journal-title":"Cell. Mol. Life Sci."},{"key":"1348_CR7","doi-asserted-by":"publisher","first-page":"a022863","DOI":"10.1101\/cshperspect.a022863","volume":"5","author":"M Barker-Haliski","year":"2015","unstructured":"Barker-Haliski, M. & White, H. S. Glutamatergic mechanisms associated with seizures and epilepsy. Cold Spring Harb. Perspect. Med. 5, a022863 (2015).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1348_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.579953","volume":"14","author":"DW Choi","year":"2020","unstructured":"Choi, D. W. Excitotoxicity: still hammering the ischemic brain in 2020. Front. Neurosci. 14, 579953 (2020).","journal-title":"Front. Neurosci."},{"key":"1348_CR9","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S1474-4422(16)30165-X","volume":"15","author":"R Macrez","year":"2016","unstructured":"Macrez, R., Stys, P. K., Vivien, D., Lipton, S. A. & Docagne, F. Mechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities. Lancet. Neurol. 15, 1089\u20131102 (2016).","journal-title":"Lancet. Neurol."},{"key":"1348_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/jnc.15811","volume":"166","author":"JV Andersen","year":"2023","unstructured":"Andersen, J. V. & Schousboe, A. Milestone Review: Metabolic dynamics of glutamate and GABA mediated neurotransmission\u2014the essential roles of astrocytes. J. Neurochem. 166, 109\u2013137 (2023).","journal-title":"J. Neurochem."},{"key":"1348_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/aps.2009.24","volume":"30","author":"XX Dong","year":"2009","unstructured":"Dong, X. X., Wang, Y. & Qin, Z. H. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol. Sin. 30, 379\u2013387 (2009).","journal-title":"Acta Pharmacol. Sin."},{"key":"1348_CR12","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1093\/brain\/awae039","volume":"147","author":"GL Odierna","year":"2024","unstructured":"Odierna, G. L. et al. How do we get from hyperexcitability to excitotoxicity in amyotrophic lateral sclerosis? Brain 147, 1610\u20131621 (2024).","journal-title":"Brain"},{"key":"1348_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jphs.2020.07.011","volume":"144","author":"L Iovino","year":"2020","unstructured":"Iovino, L., Tremblay, M. E. & Civiero, L. Glutamate-induced excitotoxicity in Parkinson\u2019s disease: the role of glial cells. J. Pharmacol. Sci. 144, 151\u2013164 (2020).","journal-title":"J. Pharmacol. Sci."},{"key":"1348_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.immuni.2010.08.018","volume":"33","author":"V Siffrin","year":"2010","unstructured":"Siffrin, V. et al. In vivo imaging of partially reversible TH17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity 33, 424\u2013436 (2010).","journal-title":"Immunity"},{"key":"1348_CR15","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI126381","volume":"130","author":"K Birkner","year":"2020","unstructured":"Birkner, K. et al. \u03b21-Integrin- and KV1.3 channel-dependent signaling stimulates glutamate release from TH17 cells. J. Clin. Invest. 130, 715\u2013732 (2020).","journal-title":"J. Clin. Invest."},{"key":"1348_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41586-024-08474-x","volume":"638","author":"MA Wheeler","year":"2025","unstructured":"Wheeler, M. A. & Quintana, F. J. The neuroimmune connectome in health and disease. Nature 638, 333\u2013342 (2025).","journal-title":"Nature"},{"key":"1348_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41392-024-01958-2","volume":"9","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Pyroptosis in health and disease: mechanisms, regulation and clinical perspective. Signal. Transduct. Target. Ther. 9, 245 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1348_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrn3710","volume":"15","author":"GC Brown","year":"2014","unstructured":"Brown, G. C. & Neher, J. J. Microglial phagocytosis of live neurons. Nat. Rev. Neurosci. 15, 209\u2013216 (2014).","journal-title":"Nat. Rev. Neurosci."},{"key":"1348_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2298-2","volume":"11","author":"J Li","year":"2020","unstructured":"Li, J. et al. Ferroptosis: past, present and future. Cell Death Dis. 11, 88 (2020).","journal-title":"Cell Death Dis."},{"key":"1348_CR20","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/epi.16571","volume":"61","author":"C Steriade","year":"2020","unstructured":"Steriade, C. et al. Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: conceptual definitions. Epilepsia 61, 1341\u20131351 (2020).","journal-title":"Epilepsia"},{"key":"1348_CR21","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41577-021-00543-w","volume":"21","author":"H Pr\u00fcss","year":"2021","unstructured":"Pr\u00fcss, H. Autoantibodies in neurological disease. Nat. Rev. Immunol. 21, 798\u2013813 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1348_CR22","volume":"218","author":"J Kreye","year":"2021","unstructured":"Kreye, J. et al. Encephalitis patient-derived monoclonal GABAA receptor antibodies cause epileptic seizures. J. Exp. Med. 218, e20210012 (2021).","journal-title":"J. Exp. Med."},{"key":"1348_CR23","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1093\/brain\/awae163","volume":"147","author":"Z Jamet","year":"2024","unstructured":"Jamet, Z. et al. NMDA receptor autoantibodies primarily impair the extrasynaptic compartment. Brain 147, 2745\u20132760 (2024).","journal-title":"Brain"},{"key":"1348_CR24","doi-asserted-by":"publisher","first-page":"106175","DOI":"10.18632\/oncotarget.22589","volume":"8","author":"F Shimizu","year":"2017","unstructured":"Shimizu, F. & Ransohoff, R. M. GRP78 autoantibodies initiate the breakdown of the blood\u2013brain barrier in neuromyelitis optica. Oncotarget 8, 106175\u2013106176 (2017).","journal-title":"Oncotarget"},{"key":"1348_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2025.1749755","volume":"19","author":"JJ Garrido","year":"2025","unstructured":"Garrido, J. J. Modulation of axon excitable domains by astrocytes and microglia. Front. Cell Neurosci. 19, 1749755 (2025).","journal-title":"Front. Cell Neurosci."},{"key":"1348_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41593-020-00756-7","volume":"24","author":"M Merlini","year":"2021","unstructured":"Merlini, M. et al. Microglial Gi-dependent dynamics regulate brain network hyperexcitability. Nat. Neurosci. 24, 19\u201323 (2021).","journal-title":"Nat. Neurosci."},{"key":"1348_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado7829","volume":"11","author":"S Zhao","year":"2025","unstructured":"Zhao, S. et al. Chemogenetic activation of microglial Gi signaling decreases microglial surveillance and impairs neuronal synchronization. Sci. Adv. 11, eado7829 (2025).","journal-title":"Sci. Adv."},{"key":"1348_CR28","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1126\/science.aax6752","volume":"367","author":"C Cser\u00e9p","year":"2020","unstructured":"Cser\u00e9p, C. et al. Microglia monitor and protect neuronal function through specialized somatic purinergic junctions. Science 367, 528\u2013537 (2020).","journal-title":"Science"},{"key":"1348_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-020-2777-8","volume":"586","author":"A Badimon","year":"2020","unstructured":"Badimon, A. et al. Negative feedback control of neuronal activity by microglia. Nature 586, 417\u2013423 (2020).","journal-title":"Nature"},{"key":"1348_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03328-9","volume":"22","author":"AB Feichtenbiner","year":"2025","unstructured":"Feichtenbiner, A. B. et al. Satellite microglia: marker of traumatic brain injury and regulator of neuronal excitability. J. Neuroinflammation 22, 9 (2025).","journal-title":"J. Neuroinflammation"},{"key":"1348_CR31","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/s41593-025-01979-2","volume":"28","author":"Z-P Chen","year":"2025","unstructured":"Chen, Z.-P. et al. GABA-dependent microglial elimination of inhibitory synapses underlies neuronal hyperexcitability in epilepsy. Nat. Neurosci. 28, 1404\u20131417 (2025).","journal-title":"Nat. Neurosci."},{"key":"1348_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-019-0850-z","volume":"7","author":"TA van Wageningen","year":"2019","unstructured":"van Wageningen, T. A. et al. Regulation of microglial TMEM119 and P2RY12 immunoreactivity in multiple sclerosis white and grey matter lesions is dependent on their inflammatory environment. Acta Neuropathol. Commun. 7, 206 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"1348_CR33","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/brain\/awx113","volume":"140","author":"T Zrzavy","year":"2017","unstructured":"Zrzavy, T. et al. Loss of \u2018homeostatic\u2019 microglia and patterns of their activation in active multiple sclerosis. Brain 140, 1900\u20131913 (2017).","journal-title":"Brain"},{"key":"1348_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab011","volume":"3","author":"J Maeda","year":"2021","unstructured":"Maeda, J. et al. Distinct microglial response against Alzheimer\u2019s amyloid and tau pathologies characterized by P2Y12 receptor. Brain Commun. 3, fcab011 (2021).","journal-title":"Brain Commun."},{"key":"1348_CR35","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.cell.2025.02.022","volume":"188","author":"K Kim","year":"2025","unstructured":"Kim, K. et al. Meningeal lymphatics\u2013microglia axis regulates synaptic physiology. Cell 188, 2705\u20132719.e23 (2025).","journal-title":"Cell"},{"key":"1348_CR36","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1007\/s12035-018-1457-2","volume":"56","author":"TY Hung","year":"2019","unstructured":"Hung, T. Y., Chu, F. L., Wu, D. C., Wu, S. N. & Huang, C. W. The protective role of peroxisome proliferator-activated receptor-\u03b3 in seizure and neuronal excitotoxicity. Mol. Neurobiol. 56, 5497\u20135506 (2019).","journal-title":"Mol. Neurobiol."},{"key":"1348_CR37","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4062\/biomolther.2014.146","volume":"23","author":"CH Lee","year":"2015","unstructured":"Lee, C. H. et al. Effect of pioglitazone on excitotoxic neuronal damage in the mouse hippocampus. Biomol. Ther. 23, 261\u2013267 (2015).","journal-title":"Biomol. Ther."},{"key":"1348_CR38","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.expneurol.2017.06.009","volume":"295","author":"SK Wyatt","year":"2017","unstructured":"Wyatt, S. K., Witt, T., Barbaro, N. M., Cohen-Gadol, A. A. & Brewster, A. L. Enhanced classical complement pathway activation and altered phagocytosis signaling molecules in human epilepsy. Exp. Neurol. 295, 184\u2013193 (2017).","journal-title":"Exp. Neurol."},{"key":"1348_CR39","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s43587-022-00281-1","volume":"2","author":"B Dejanovic","year":"2022","unstructured":"Dejanovic, B. et al. Complement C1q-dependent excitatory and inhibitory synapse elimination by astrocytes and microglia in Alzheimer\u2019s disease mouse models. Nat. Aging 2, 837\u2013850 (2022).","journal-title":"Nat. Aging"},{"key":"1348_CR40","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1016\/j.immuni.2025.08.016","volume":"58","author":"M Xie","year":"2025","unstructured":"Xie, M. et al. Rod-shaped microglia interact with neuronal dendrites to attenuate cortical excitability during TDP-43-related neurodegeneration. Immunity 58, 3113\u20133129.e8 (2025).","journal-title":"Immunity"},{"key":"1348_CR41","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow, S. A. et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481\u2013487 (2017).","journal-title":"Nature"},{"key":"1348_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112010","volume":"42","author":"N Yousefpour","year":"2023","unstructured":"Yousefpour, N. et al. Time-dependent and selective microglia-mediated removal of spinal synapses in neuropathic pain. Cell Rep. 42, 112010 (2023).","journal-title":"Cell Rep."},{"key":"1348_CR43","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s12264-021-00750-4","volume":"37","author":"GT Jiang","year":"2021","unstructured":"Jiang, G. T. et al. Complement C3 aggravates post-epileptic neuronal injury via activation of TRPV1. Neurosci. Bull. 37, 1427\u20131440 (2021).","journal-title":"Neurosci. Bull."},{"key":"1348_CR44","first-page":"362","volume":"47","author":"S Nandi","year":"2025","unstructured":"Nandi, S., de Deus, J. L., Faborode, O. S. & Nandi, S. Synaptic pruning by microglia: lessons from genetic studies in mice. Dev. Neurosci. 47, 362\u2013382 (2025).","journal-title":"Dev. Neurosci."},{"key":"1348_CR45","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022113246","volume":"42","author":"J Rueda-Carrasco","year":"2023","unstructured":"Rueda-Carrasco, J. et al. Microglia-synapse engulfment via PtdSer\u2013TREM2 ameliorates neuronal hyperactivity in Alzheimer\u2019s disease models. EMBO J. 42, e113246 (2023).","journal-title":"EMBO J."},{"key":"1348_CR46","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3233\/JAD-210041","volume":"88","author":"M Stoiljkovic","year":"2022","unstructured":"Stoiljkovic, M., Gutierrez, K. O., Kelley, C., Horvath, T. L. & Haj\u00f3s, M. TREM2 deficiency disrupts network oscillations leading to epileptic activity and aggravates amyloid-\u03b2-related hippocampal pathophysiology in mice. J. Alzheimers Dis. 88, 837\u2013847 (2022).","journal-title":"J. Alzheimers Dis."},{"key":"1348_CR47","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13421","volume":"329","author":"A Hollis","year":"2025","unstructured":"Hollis, A. & Lukens, J. R. Role of inflammasomes and neuroinflammation in epilepsy. Immunol. Rev. 329, e13421 (2025).","journal-title":"Immunol. Rev."},{"key":"1348_CR48","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41423-025-01275-w","volume":"22","author":"W Xu","year":"2025","unstructured":"Xu, W., Huang, Y. & Zhou, R. NLRP3 inflammasome in neuroinflammation and central nervous system diseases. Cell. Mol. Immunol. 22, 341\u2013355 (2025).","journal-title":"Cell. Mol. Immunol."},{"key":"1348_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.904225","volume":"13","author":"S Zhang","year":"2022","unstructured":"Zhang, S., Chen, F., Zhai, F. & Liang, S. Role of HMGB1\/TLR4 and IL-1\u03b2\/IL-1R1 signaling pathways in epilepsy. Front. Neurol. 13, 904225 (2022).","journal-title":"Front. Neurol."},{"key":"1348_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8069-9-16","volume":"9","author":"T Liu","year":"2013","unstructured":"Liu, T., Jiang, C. Y., Fujita, T., Luo, S. W. & Kumamoto, E. Enhancement by interleukin-1\u03b2 of AMPA and NMDA receptor-mediated currents in adult rat spinal superficial dorsal horn neurons. Mol. Pain. 9, 16 (2013).","journal-title":"Mol. Pain."},{"key":"1348_CR51","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/ana.25698","volume":"87","author":"AA Korgaonkar","year":"2020","unstructured":"Korgaonkar, A. A. et al. Toll-like receptor 4 signaling in neurons enhances calcium-permeable \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor currents and drives post-traumatic epileptogenesis. Ann. Neurol. 87, 497\u2013515 (2020).","journal-title":"Ann. Neurol."},{"key":"1348_CR52","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fncel.2014.00006","volume":"8","author":"DS Samways","year":"2014","unstructured":"Samways, D. S., Li, Z. & Egan, T. M. Principles and properties of ion flow in P2X receptors. Front. Cell Neurosci. 8, 6 (2014).","journal-title":"Front. Cell Neurosci."},{"key":"1348_CR53","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.immuni.2024.12.008","volume":"58","author":"C Iadecola","year":"2025","unstructured":"Iadecola, C. & Anrather, J. The immunology of stroke and dementia. Immunity 58, 18\u201339 (2025).","journal-title":"Immunity"},{"key":"1348_CR54","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41593-020-00773-6","volume":"24","author":"P Mastorakos","year":"2021","unstructured":"Mastorakos, P. et al. Temporally distinct myeloid cell responses mediate damage and repair after cerebrovascular injury. Nat. Neurosci. 24, 245\u2013258 (2021).","journal-title":"Nat. Neurosci."},{"key":"1348_CR55","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/glia.24377","volume":"71","author":"VG Hernandez","year":"2023","unstructured":"Hernandez, V. G. et al. Translatome analysis reveals microglia and astrocytes to be distinct regulators of inflammation in the hyperacute and acute phases after stroke. Glia 71, 1960\u20131984 (2023).","journal-title":"Glia"},{"key":"1348_CR56","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abk0135","volume":"14","author":"L Bitar","year":"2022","unstructured":"Bitar, L. et al. Inhibition of the enzyme autotaxin reduces cortical excitability and ameliorates the outcome in stroke. Sci. Transl. Med. 14, eabk0135 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1348_CR57","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1038\/s41380-018-0053-1","volume":"23","author":"C Thalman","year":"2018","unstructured":"Thalman, C. et al. Synaptic phospholipids as a new target for cortical hyperexcitability and E\/I balance in psychiatric disorders. Mol. Psychiatry 23, 1699\u20131710 (2018).","journal-title":"Mol. Psychiatry"},{"key":"1348_CR58","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1038\/s41380-024-02598-2","volume":"29","author":"O T\u00fcscher","year":"2024","unstructured":"T\u00fcscher, O. et al. Altered cortical synaptic lipid signaling leads to intermediate phenotypes of mental disorders. Mol. Psychiatry 29, 3537\u20133552 (2024).","journal-title":"Mol. Psychiatry"},{"key":"1348_CR59","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.neuron.2019.03.029","volume":"102","author":"J Yang","year":"2019","unstructured":"Yang, J. et al. Glutamate-releasing SWELL1 channel in astrocytes modulates synaptic transmission and promotes brain damage in stroke. Neuron 102, 813\u2013827.e6 (2019).","journal-title":"Neuron"},{"key":"1348_CR60","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202411","volume":"218","author":"S Heindl","year":"2021","unstructured":"Heindl, S. et al. Chronic T cell proliferation in brains after stroke could interfere with the efficacy of immunotherapies. J. Exp. Med. 218, e20202411 (2021).","journal-title":"J. Exp. Med."},{"key":"1348_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30054-8","volume":"13","author":"MJ Lazarczyk","year":"2023","unstructured":"Lazarczyk, M. J. et al. The intracellular domain of major histocompatibility class-I proteins is essential for maintaining excitatory spine density and synaptic ultrastructure in the brain. Sci. Rep. 13, 6448 (2023).","journal-title":"Sci. Rep."},{"key":"1348_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.664312","volume":"15","author":"Y Pan","year":"2021","unstructured":"Pan, Y. et al. Inhibition of perforin-mediated neurotoxicity attenuates neurological deficits after ischemic stroke. Front. Cell. Neurosci. 15, 664312 (2021).","journal-title":"Front. Cell. Neurosci."},{"key":"1348_CR63","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abk3147","volume":"8","author":"ME Ivanova","year":"2022","unstructured":"Ivanova, M. E. et al. The pore conformation of lymphocyte perforin. Sci. Adv. 8, eabk3147 (2022).","journal-title":"Sci. Adv."},{"key":"1348_CR64","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41577-018-0009-3","volume":"18","author":"P Golstein","year":"2018","unstructured":"Golstein, P. & Griffiths, G. M. An early history of T cell-mediated cytotoxicity. Nat. Reviews. Immunol. 18, 527\u2013535 (2018).","journal-title":"Nat. Reviews. Immunol."},{"key":"1348_CR65","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1073\/pnas.1315943111","volume":"111","author":"Y Gan","year":"2014","unstructured":"Gan, Y. et al. Ischemic neurons recruit natural killer cells that accelerate brain infarction. Proc. Natl Acad. Sci. USA 111, 2704\u20132709 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1348_CR66","doi-asserted-by":"publisher","first-page":"15397","DOI":"10.1523\/JNEUROSCI.4339-09.2009","volume":"29","author":"SG Meuth","year":"2009","unstructured":"Meuth, S. G. et al. Cytotoxic CD8+ T cell\u2013neuron Interactions: perforin-dependent electrical silencing precedes but is not causally linked to neuronal cell death. J. Neurosci. 29, 15397\u201315409 (2009).","journal-title":"J. Neurosci."},{"key":"1348_CR67","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nm.4068","volume":"22","author":"C Benakis","year":"2016","unstructured":"Benakis, C. et al. Commensal microbiota affects ischemic stroke outcome by regulating intestinal \u03b3\u03b4 T cells. Nat. Med. 22, 516\u2013523 (2016).","journal-title":"Nat. Med."},{"key":"1348_CR68","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aay5199","volume":"4","author":"M Ribeiro","year":"2019","unstructured":"Ribeiro, M. et al. Meningeal \u03b3\u03b4 T cell-derived IL-17 controls synaptic plasticity and short-term memory. Sci. Immunol. 4, eaay5199 (2019).","journal-title":"Sci. Immunol."},{"key":"1348_CR69","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.celrep.2019.10.085","volume":"29","author":"H Luo","year":"2019","unstructured":"Luo, H. et al. Interleukin-17 regulates neuron\u2013glial communications, synaptic transmission, and neuropathic pain after chemotherapy. Cell Rep. 29, 2384\u20132397.e5 (2019).","journal-title":"Cell Rep."},{"key":"1348_CR70","doi-asserted-by":"publisher","first-page":"917598","DOI":"10.3389\/fnmol.2022.917598","volume":"15","author":"I-Y Choi","year":"2022","unstructured":"Choi, I.-Y., Cho, M.-L. & Cho, K.-O. Interleukin-17A mediates hippocampal damage and aberrant neurogenesis contributing to epilepsy-associated anxiety. Front. Mol. Neurosci. 15, 917598 (2022).","journal-title":"Front. Mol. Neurosci."},{"key":"1348_CR71","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1084\/jem.20171285","volume":"215","author":"D Xu","year":"2018","unstructured":"Xu, D. et al. Peripherally derived T regulatory and \u03b3\u03b4 T cells have opposing roles in the pathogenesis of intractable pediatric epilepsy. J. Exp. Med. 215, 1169\u20131186 (2018).","journal-title":"J. Exp. Med."},{"key":"1348_CR72","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.msard.2016.11.006","volume":"11","author":"M Kostic","year":"2017","unstructured":"Kostic, M., Zivkovic, N., Cvetanovic, A., Stojanovic, I. & Colic, M. IL-17 signalling in astrocytes promotes glutamate excitotoxicity: indications for the link between inflammatory and neurodegenerative events in multiple sclerosis. Multiple Scler. Relat. Disord. 11, 12\u201317 (2017).","journal-title":"Multiple Scler. Relat. Disord."},{"key":"1348_CR73","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.stem.2018.06.015","volume":"23","author":"A Sommer","year":"2018","unstructured":"Sommer, A. et al. TH17 lymphocytes induce neuronal cell death in a human iPSC-based model of Parkinson\u2019s disease. Cell Stem Cell 23, 123\u2013131.e6 (2018).","journal-title":"Cell Stem Cell"},{"key":"1348_CR74","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrn.2016.178","volume":"18","author":"DJ Surmeier","year":"2017","unstructured":"Surmeier, D. J., Obeso, J. A. & Halliday, G. M. Selective neuronal vulnerability in Parkinson disease. Nat. Rev. Neurosci. 18, 101\u2013113 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"1348_CR75","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abp8701","volume":"8","author":"E Zampese","year":"2022","unstructured":"Zampese, E. et al. Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopaminergic neurons. Sci. Adv. 8, eabp8701 (2022).","journal-title":"Sci. Adv."},{"key":"1348_CR76","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1093\/brain\/awad150","volume":"146","author":"P Calabresi","year":"2023","unstructured":"Calabresi, P., Di Lazzaro, G., Marino, G., Campanelli, F. & Ghiglieri, V. Advances in understanding the function of \u03b1-synuclein: implications for Parkinson\u2019s disease. Brain 146, 3587\u20133597 (2023).","journal-title":"Brain"},{"key":"1348_CR77","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1093\/brain\/awae177","volume":"147","author":"C Roodveldt","year":"2024","unstructured":"Roodveldt, C. et al. The immune system in Parkinson\u2019s disease: what we know so far. Brain 147, 3306\u20133324 (2024).","journal-title":"Brain"},{"key":"1348_CR78","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41531-024-00867-z","volume":"11","author":"L Chen","year":"2025","unstructured":"Chen, L., Chehade, H. D. & Chu, H.-Y. Motor cortical neuronal hyperexcitability associated with \u03b1-synuclein aggregation. npj Parkinsons Dis. 11, 18 (2025).","journal-title":"npj Parkinsons Dis."},{"key":"1348_CR79","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s40478-021-01203-9","volume":"9","author":"M Lin","year":"2021","unstructured":"Lin, M. et al. In Parkinson\u2019s patient-derived dopamine neurons, the triplication of \u03b1-synuclein locus induces distinctive firing pattern by impeding D2 receptor autoinhibition. Acta Neuropathol. Commun. 9, 107 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"1348_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-018-0241-0","volume":"13","author":"K Yamada","year":"2018","unstructured":"Yamada, K. & Iwatsubo, T. Extracellular \u03b1-synuclein levels are regulated by neuronal activity. Mol. Neurodegener. 13, 9 (2018).","journal-title":"Mol. Neurodegener."},{"key":"1348_CR81","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00401-020-02227-6","volume":"140","author":"Q Wu","year":"2020","unstructured":"Wu, Q. et al. Neuronal activity modulates \u03b1-synuclein aggregation and spreading in organotypic brain slice cultures and in vivo. Acta Neuropathol. 140, 831\u2013849 (2020).","journal-title":"Acta Neuropathol."},{"key":"1348_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-019-0814-3","volume":"7","author":"T Torre-Muruzabal","year":"2019","unstructured":"Torre-Muruzabal, T. et al. Chronic nigral neuromodulation aggravates behavioral deficits and synaptic changes in an \u03b1-synuclein based rat model for Parkinson\u2019s disease. Acta Neuropathol. Commun. 7, 160 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"1348_CR83","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1093\/brain\/awab242","volume":"144","author":"A Tozzi","year":"2021","unstructured":"Tozzi, A. et al. Dopamine-dependent early synaptic and motor dysfunctions induced by \u03b1-synuclein in the nigrostriatal circuit. Brain 144, 3477\u20133491 (2021).","journal-title":"Brain"},{"key":"1348_CR84","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac165","volume":"4","author":"AS Kulkarni","year":"2022","unstructured":"Kulkarni, A. S., Burns, M. R., Brundin, P. & Wesson, D. W. Linking \u03b1-synuclein-induced synaptopathy and neural network dysfunction in early Parkinson\u2019s disease. Brain Commun. 4, fcac165 (2022).","journal-title":"Brain Commun."},{"key":"1348_CR85","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/mds.28375","volume":"36","author":"S Mullin","year":"2021","unstructured":"Mullin, S. et al. Brain microglial activation increased in glucocerebrosidase (GBA) mutation carriers without Parkinson\u2019s disease. Mov. Disord. 36, 774\u2013779 (2021).","journal-title":"Mov. Disord."},{"key":"1348_CR86","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/brain\/awab446","volume":"145","author":"S Smajic","year":"2022","unstructured":"Smajic, S. et al. Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state. Brain 145, 964\u2013978 (2022).","journal-title":"Brain"},{"key":"1348_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04049-0","volume":"12","author":"T-W Chou","year":"2021","unstructured":"Chou, T.-W. et al. Fibrillar \u03b1-synuclein induces neurotoxic astrocyte activation via RIP kinase signaling and NF-\u03baB. Cell Death Dis. 12, 756 (2021).","journal-title":"Cell Death Dis."},{"key":"1348_CR88","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00401-018-1907-y","volume":"137","author":"CD Hughes","year":"2019","unstructured":"Hughes, C. D. et al. Picomolar concentrations of oligomeric \u03b1-synuclein sensitizes TLR4 to play an initiating role in Parkinson\u2019s disease pathogenesis. Acta Neuropathol. 137, 103\u2013120 (2019).","journal-title":"Acta Neuropathol."},{"key":"1348_CR89","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1523\/JNEUROSCI.1871-20.2020","volume":"41","author":"D Trudler","year":"2021","unstructured":"Trudler, D. et al. \u03b1-Synuclein oligomers induce glutamate release from astrocytes and excessive extrasynaptic NMDAR activity in neurons, thus contributing to synapse loss. J. Neurosci. 41, 2264\u20132273 (2021).","journal-title":"J. Neurosci."},{"key":"1348_CR90","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.4049\/jimmunol.2100035","volume":"207","author":"H Scheiblich","year":"2021","unstructured":"Scheiblich, H. et al. Microglial NLRP3 inflammasome activation upon TLR2 and TLR5 ligation by distinct \u03b1-synuclein assemblies. J. Immunol. 207, 2143\u20132154 (2021).","journal-title":"J. Immunol."},{"key":"1348_CR91","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/glia.23970","volume":"69","author":"AF Pike","year":"2021","unstructured":"Pike, A. F. et al. \u03b1-Synuclein evokes NLRP3 inflammasome-mediated IL-1\u03b2 secretion from primary human microglia. Glia 69, 1413\u20131428 (2021).","journal-title":"Glia"},{"key":"1348_CR92","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1111\/j.1471-4159.2007.04487.x","volume":"101","author":"SW Barger","year":"2007","unstructured":"Barger, S. W., Goodwin, M. E., Porter, M. M. & Beggs, M. L. Glutamate release from activated microglia requires the oxidative burst and lipid peroxidation. J. Neurochem. 101, 1205\u20131213 (2007).","journal-title":"J. Neurochem."},{"key":"1348_CR93","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.coph.2015.10.001","volume":"26","author":"SH Chen","year":"2016","unstructured":"Chen, S. H., Oyarzabal, E. A. & Hong, J. S. Critical role of the Mac1\/NOX2 pathway in mediating reactive microgliosis-generated chronic neuroinflammation and progressive neurodegeneration. Curr. Opin. Pharmacol. 26, 54\u201360 (2016).","journal-title":"Curr. Opin. Pharmacol."},{"key":"1348_CR94","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.expneurol.2011.10.025","volume":"233","author":"KA Kigerl","year":"2012","unstructured":"Kigerl, K. A. et al. System xc\u2013 regulates microglia and macrophage glutamate excitotoxicity in vivo. Exp. Neurol. 233, 333\u2013341 (2012).","journal-title":"Exp. Neurol."},{"key":"1348_CR95","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.bbi.2023.04.008","volume":"111","author":"BD Hobson","year":"2023","unstructured":"Hobson, B. D. et al. Conserved and cell type-specific transcriptional responses to IFN-\u03b3 in the ventral midbrain. Brain Behav. Immun. 111, 277\u2013291 (2023).","journal-title":"Brain Behav. Immun."},{"key":"1348_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15626-w","volume":"11","author":"CS Lindestam Arlehamn","year":"2020","unstructured":"Lindestam Arlehamn, C. S. et al. \u03b1-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson\u2019s disease. Nat. Commun. 11, 1875 (2020).","journal-title":"Nat. Commun."},{"key":"1348_CR97","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.3233\/JPD-223152","volume":"12","author":"E Contaldi","year":"2022","unstructured":"Contaldi, E., Magistrelli, L. & Comi, C. T lymphocytes in Parkinson\u2019s disease. J. Parkinsons Dis. 12, S65\u2013S74 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"1348_CR98","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-025-03359-w","volume":"22","author":"E Furusawa-Nishii","year":"2025","unstructured":"Furusawa-Nishii, E. et al. \u03b1-Synuclein orchestrates TH17 responses as antigen and adjuvant in Parkinson\u2019s disease. J. Neuroinflammation 22, 38 (2025).","journal-title":"J. Neuroinflammation"},{"key":"1348_CR99","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41531-025-00882-8","volume":"11","author":"E Gerasimova","year":"2025","unstructured":"Gerasimova, E. et al. Novel co-culture model of T cells and midbrain organoids for investigating neurodegeneration in Parkinson\u2019s disease. npj Parkinsons Dis. 11, 36 (2025).","journal-title":"npj Parkinsons Dis."},{"key":"1348_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02024-7","volume":"12","author":"H Targa Dias Anastacio","year":"2022","unstructured":"Targa Dias Anastacio, H., Matosin, N. & Ooi, L. Neuronal hyperexcitability in Alzheimer\u2019s disease: what are the drivers behind this aberrant phenotype? Transl. Psychiatry 12, 257 (2022).","journal-title":"Transl. Psychiatry"},{"key":"1348_CR101","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-024-01104-7","volume":"25","author":"MT Heneka","year":"2025","unstructured":"Heneka, M. T. et al. Neuroinflammation in Alzheimer disease. Nat. Rev. Immunol. 25, 321\u2013352 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"1348_CR102","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","volume":"8","author":"W Zhang","year":"2023","unstructured":"Zhang, W., Xiao, D., Mao, Q. & Xia, H. Role of neuroinflammation in neurodegeneration development. Signal. Transduct. Target. Ther. 8, 267 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1348_CR103","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/ana.25365","volume":"84","author":"RJ Bevan","year":"2018","unstructured":"Bevan, R. J. et al. Meningeal inflammation and cortical demyelination in acute multiple sclerosis. Ann. Neurol. 84, 829\u2013842 (2018).","journal-title":"Ann. Neurol."},{"key":"1348_CR104","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","volume":"403","author":"D Jakimovski","year":"2024","unstructured":"Jakimovski, D. et al. Multiple sclerosis. Lancet 403, 183\u2013202 (2024).","journal-title":"Lancet"},{"key":"1348_CR105","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s11055-020-00953-8","volume":"50","author":"US Kuzmina","year":"2020","unstructured":"Kuzmina, U. S., Zainullina, L. F., Vakhitov, V. A., Bakhtiyarova, K. Z. & Vakhitova, Y. V. The role of glutamate in the pathogenesis of multiple sclerosis. Neurosci. Behav. Physiol. 50, 669\u2013675 (2020).","journal-title":"Neurosci. Behav. Physiol."},{"key":"1348_CR106","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41582-021-00581-x","volume":"18","author":"HYF Yong","year":"2022","unstructured":"Yong, H. Y. F. & Yong, V. W. Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis. Nat. Rev. Neurol. 18, 40\u201355 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"1348_CR107","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2425081122","volume":"122","author":"A Fruitman Davidi","year":"2025","unstructured":"Fruitman Davidi, A. et al. Dural ectopic lymphatic structures accumulate during aging and exhibit dysregulation in neurodegenerative diseases. Proc. Natl Acad. Sci. USA 122, e2425081122 (2025).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1348_CR108","doi-asserted-by":"publisher","DOI":"10.1172\/JCI196905","volume":"136","author":"S Yang","year":"2026","unstructured":"Yang, S. et al. Ectopic B lymphocyte follicles exacerbate ischemic brain damage via MIF-CD74\/CXCR4 and interferon signaling. J. Clin. Invest. 136, e196905 (2026).","journal-title":"J. Clin. Invest."},{"key":"1348_CR109","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1093\/brain\/awr182","volume":"134","author":"OW Howell","year":"2011","unstructured":"Howell, O. W. et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 134, 2755\u20132771 (2011).","journal-title":"Brain"},{"key":"1348_CR110","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41586-025-09378-0","volume":"646","author":"F L\u00e4derach","year":"2025","unstructured":"L\u00e4derach, F. et al. EBV induces CNS homing of B cells attracting inflammatory T cells. Nature 646, 171\u2013179 (2025).","journal-title":"Nature"},{"key":"1348_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102027","volume":"6","author":"I Jelcic","year":"2025","unstructured":"Jelcic, I. et al. T-bet+CXCR3+ B cells drive hyperreactive B\u2013T cell interactions in multiple sclerosis. Cell Rep. Med. 6, 102027 (2025).","journal-title":"Cell Rep. Med."},{"key":"1348_CR112","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/ana.22230","volume":"68","author":"R Magliozzi","year":"2010","unstructured":"Magliozzi, R. et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann. Neurol. 68, 477\u2013493 (2010).","journal-title":"Ann. Neurol."},{"key":"1348_CR113","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00401-021-02274-7","volume":"141","author":"C Picon","year":"2021","unstructured":"Picon, C. et al. Neuron-specific activation of necroptosis signaling in multiple sclerosis cortical grey matter. Acta Neuropathol.141, 585\u2013604 (2021).","journal-title":"Acta Neuropathol."},{"key":"1348_CR114","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adx2652","volume":"17","author":"J Shin","year":"2025","unstructured":"Shin, J. et al. Bruton\u2019s tyrosine kinase inhibitors rescue neuronal impairment caused by B cell-mediated lymphotoxin-\u03b1 release. Sci. Transl. Med. 17, eadx2652 (2025).","journal-title":"Sci. Transl. Med."},{"key":"1348_CR115","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/ncb2883","volume":"16","author":"Z Cai","year":"2014","unstructured":"Cai, Z. et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat. Cell Biol. 16, 55\u201365 (2014).","journal-title":"Nat. Cell Biol."},{"key":"1348_CR116","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S0092-8674(03)01017-1","volume":"115","author":"M Aarts","year":"2003","unstructured":"Aarts, M. et al. A key role for TRPM7 channels in anoxic neuronal death. Cell 115, 863\u2013877 (2003).","journal-title":"Cell"},{"key":"1348_CR117","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3390\/ijms24021639","volume":"24","author":"K Schwarz","year":"2023","unstructured":"Schwarz, K. & Schmitz, F. Synapse dysfunctions in multiple sclerosis. Int. J. Mol. Sci. 24, 1639 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1348_CR118","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/s41593-018-0193-2","volume":"21","author":"E Ellwardt","year":"2018","unstructured":"Ellwardt, E. et al. Maladaptive cortical hyperactivity upon recovery from experimental autoimmune encephalomyelitis. Nat. Neurosci. 21, 1392\u20131403 (2018).","journal-title":"Nat. Neurosci."},{"key":"1348_CR119","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1016\/j.cell.2024.05.031","volume":"187","author":"MS Woo","year":"2024","unstructured":"Woo, M. S. et al. STING orchestrates the neuronal inflammatory stress response in multiple sclerosis. Cell 187, 4043\u20134060.e30 (2024).","journal-title":"Cell"},{"key":"1348_CR120","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00401-021-02293-4","volume":"141","author":"L van Olst","year":"2021","unstructured":"van Olst, L. et al. Meningeal inflammation in multiple sclerosis induces phenotypic changes in cortical microglia that differentially associate with neurodegeneration. Acta Neuropathol. 141, 881\u2013899 (2021).","journal-title":"Acta Neuropathol."},{"key":"1348_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2025.153035","volume":"230","author":"K Champagne-Jorgensen","year":"2025","unstructured":"Champagne-Jorgensen, K. et al. A multi-omic pipeline identifies complement as a driver of age-dependent progression in a model of multiple sclerosis. Immunobiology 230, 153035 (2025).","journal-title":"Immunobiology"},{"key":"1348_CR122","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41593-020-00780-7","volume":"24","author":"M Jafari","year":"2021","unstructured":"Jafari, M. et al. Phagocyte-mediated synapse removal in cortical neuroinflammation is promoted by local calcium accumulation. Nat. Neurosci. 24, 355\u2013367 (2021).","journal-title":"Nat. Neurosci."},{"key":"1348_CR123","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/ana.24468","volume":"78","author":"L Freeman","year":"2015","unstructured":"Freeman, L. et al. The neuronal component of gray matter damage in multiple sclerosis: a [11C]flumazenil positron emission tomography study. Ann. Neurol. 78, 554\u2013567 (2015).","journal-title":"Ann. Neurol."},{"key":"1348_CR124","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1093\/brain\/awv209","volume":"138","author":"N Cawley","year":"2015","unstructured":"Cawley, N. et al. Reduced \u03b3-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis. Brain 138, 2584\u20132595 (2015).","journal-title":"Brain"},{"key":"1348_CR125","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00401-020-02258-z","volume":"141","author":"L Zoupi","year":"2021","unstructured":"Zoupi, L. et al. Selective vulnerability of inhibitory networks in multiple sclerosis. Acta Neuropathol. 141, 415\u2013429 (2021).","journal-title":"Acta Neuropathol."},{"key":"1348_CR126","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00401-021-02338-8","volume":"142","author":"V Ramaglia","year":"2021","unstructured":"Ramaglia, V. et al. Complement-associated loss of CA2 inhibitory synapses in the demyelinated hippocampus impairs memory. Acta Neuropathol. 142, 643\u2013667 (2021).","journal-title":"Acta Neuropathol."},{"key":"1348_CR127","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03326-x","volume":"21","author":"C Barros","year":"2024","unstructured":"Barros, C., Alberro, A. & Fernandes, A. Microglia and Immune cells interactions in multiple sclerosis cognitive impairment: a postmortem study. J. Neuroinflammation 21, 332 (2024).","journal-title":"J. Neuroinflammation"},{"key":"1348_CR128","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.neuron.2017.04.014","volume":"94","author":"R Boehringer","year":"2017","unstructured":"Boehringer, R. et al. Chronic loss of CA2 transmission leads to hippocampal hyperexcitability. Neuron 94, 642\u2013655.e9 (2017).","journal-title":"Neuron"},{"key":"1348_CR129","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0140-6736(04)15490-1","volume":"363","author":"KW Muir","year":"2004","unstructured":"Muir, K. W., Lees, K. R., Ford, I. & Davis, S. Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet 363, 439\u2013445 (2004).","journal-title":"Lancet"},{"key":"1348_CR130","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1056\/NEJMoa1408827","volume":"372","author":"JL Saver","year":"2015","unstructured":"Saver, J. L. et al. Prehospital use of magnesium sulfate as neuroprotection in acute stroke. N. Engl. J. Med. 372, 528\u2013536 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1348_CR131","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/S0140-6736(25)00194-1","volume":"405","author":"MD Hill","year":"2025","unstructured":"Hill, M. D. et al. Efficacy and safety of nerinetide in acute ischaemic stroke in patients undergoing endovascular thrombectomy without previous thrombolysis (ESCAPE-NEXT): a multicentre, double-blind, randomised controlled trial. Lancet 405, 560\u2013570 (2025).","journal-title":"Lancet"},{"key":"1348_CR132","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(20)30258-0","volume":"395","author":"MD Hill","year":"2020","unstructured":"Hill, M. D. et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet 395, 878\u2013887 (2020).","journal-title":"Lancet"},{"key":"1348_CR133","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1161\/STROKEAHA.122.039649","volume":"53","author":"JM Hong","year":"2022","unstructured":"Hong, J. M. et al. Nelonemdaz for patients with acute ischemic stroke undergoing endovascular reperfusion therapy: a randomized phase II trial. Stroke 53, 3250\u20133259 (2022).","journal-title":"Stroke"},{"key":"1348_CR134","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.56535","volume":"8","author":"JS Lee","year":"2025","unstructured":"Lee, J. S. et al. Nelonemdaz and patients with acute ischemic stroke and mechanical reperfusion: the RODIN randomized clinical trial. JAMA Netw. Open. 8, e2456535 (2025).","journal-title":"JAMA Netw. Open."},{"key":"1348_CR135","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/nyas.15105","volume":"1533","author":"V Dur\u00e1n Laforet","year":"2024","unstructured":"Dur\u00e1n Laforet, V. & Schafer, D. P. Microglia: activity-dependent regulators of neural circuits. Ann. N. Y. Acad. Sci. 1533, 38\u201350 (2024).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1348_CR136","first-page":"3559","volume":"22","author":"JL Zhao","year":"2020","unstructured":"Zhao, J. L. et al. Expression of TNF-\u03b1 and IL-\u03b2 can be suppressed via the PPAR-\u03b3\/mTOR signaling pathway in BV-2 microglia: a potential anti-inflammation mechanism. Mol. Med. Rep. 22, 3559\u20133565 (2020).","journal-title":"Mol. Med. Rep."},{"key":"1348_CR137","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jneuroim.2009.04.011","volume":"211","author":"CC Kaiser","year":"2009","unstructured":"Kaiser, C. C. et al. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J. Neuroimmunol. 211, 124\u2013130 (2009).","journal-title":"J. Neuroimmunol."},{"key":"1348_CR138","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-1-3","volume":"1","author":"HA Pershadsingh","year":"2004","unstructured":"Pershadsingh, H. A. et al. Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J. Neuroinflammation 1, 3 (2004).","journal-title":"J. Neuroinflammation"},{"key":"1348_CR139","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.bbi.2024.09.034","volume":"123","author":"DB Bosco","year":"2025","unstructured":"Bosco, D. B. et al. Microglial TREM2 promotes phagocytic clearance of damaged neurons after status epilepticus. Brain Behav. Immun. 123, 540\u2013555 (2025).","journal-title":"Brain Behav. Immun."},{"key":"1348_CR140","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1073\/pnas.1520398113","volume":"113","author":"N Lou","year":"2016","unstructured":"Lou, N. et al. Purinergic receptor P2RY12-dependent microglial closure of the injured blood\u2013brain barrier. Proc. Natl Acad. Sci. USA 113, 1074\u20131079 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1348_CR141","doi-asserted-by":"publisher","first-page":"10425","DOI":"10.1096\/fj.201900527R","volume":"33","author":"L Sheng","year":"2019","unstructured":"Sheng, L. et al. Microglial Trem2 induces synaptic impairment at early stage and prevents amyloidosis at late stage in APP\/PS1 mice. FASEB J. 33, 10425\u201310442 (2019).","journal-title":"FASEB J."},{"key":"1348_CR142","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070927","volume":"8","author":"CM Webster","year":"2013","unstructured":"Webster, C. M. et al. Microglial P2Y12 deficiency\/inhibition protects against brain ischemia. PLoS ONE 8, e70927 (2013).","journal-title":"PLoS ONE"},{"key":"1348_CR143","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13075-018-1664-2","volume":"20","author":"C Marchetti","year":"2018","unstructured":"Marchetti, C. et al. NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis. Arthritis Res. Ther. 20, 169 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"1348_CR144","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/nature04671","volume":"440","author":"D Stellwagen","year":"2006","unstructured":"Stellwagen, D. & Malenka, R. C. Synaptic scaling mediated by glial TNF-\u03b1. Nature 440, 1054\u20131059 (2006).","journal-title":"Nature"},{"key":"1348_CR145","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s44400-026-00091-x","volume":"2","author":"J Jaeger","year":"2026","unstructured":"Jaeger, J. et al. XPro1595 in early Alzheimer\u2019s disease with inflammation: results from the phase 2 MINDFuL trial. npj Dement. 2, 37 (2026).","journal-title":"npj Dement."},{"key":"1348_CR146","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1038\/s41591-024-03101-8","volume":"30","author":"P Eijsvogel","year":"2024","unstructured":"Eijsvogel, P. et al. Target engagement and immunogenicity of an active immunotherapeutic targeting pathological \u03b1-synuclein: a phase 1 placebo-controlled trial. Nat. Med. 30, 2631\u20132640 (2024).","journal-title":"Nat. Med."},{"key":"1348_CR147","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","volume":"19","author":"D Volc","year":"2020","unstructured":"Volc, D. et al. Safety and immunogenicity of the \u03b1-synuclein active immunotherapeutic PD01A in patients with Parkinson\u2019s disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol. 19, 591\u2013600 (2020).","journal-title":"Lancet Neurol."},{"key":"1348_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.705407","volume":"12","author":"G Pagano","year":"2021","unstructured":"Pagano, G. et al. A phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson\u2019s disease (PASADENA): rationale, design, and baseline data. Front. Neurol. 12, 705407 (2021).","journal-title":"Front. Neurol."},{"key":"1348_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107257","volume":"132","author":"T Nikolcheva","year":"2025","unstructured":"Nikolcheva, T. et al. A phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson\u2019s disease (PADOVA): rationale, design, and baseline data. Parkinsonism Relat. Disord. 132, 107257 (2025).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1348_CR150","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41531-017-0013-5","volume":"3","author":"HE Gendelman","year":"2017","unstructured":"Gendelman, H. E. et al. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson\u2019s disease trial. npj Parkinsons Dis. 3, 10 (2017).","journal-title":"npj Parkinsons Dis."},{"key":"1348_CR151","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-023-00361-1","volume":"12","author":"KE Olson","year":"2023","unstructured":"Olson, K. E. et al. An open-label multiyear study of sargramostim-treated Parkinson\u2019s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers. Transl. Neurodegener. 12, 26 (2023).","journal-title":"Transl. Neurodegener."},{"key":"1348_CR152","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","volume":"19","author":"J Kr\u00e4mer","year":"2023","unstructured":"Kr\u00e4mer, J., Bar-Or, A., Turner, T. J. & Wiendl, H. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat. Rev. Neurol. 19, 289\u2013304 (2023).","journal-title":"Nat. Rev. Neurol."},{"key":"1348_CR153","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/S1474-4422(25)00174-7","volume":"24","author":"A Bar-Or","year":"2025","unstructured":"Bar-Or, A. et al. Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study. Lancet. Neurol. 24, 656\u2013666 (2025).","journal-title":"Lancet. Neurol."},{"key":"1348_CR154","doi-asserted-by":"publisher","unstructured":"Fox, R. J. et al. Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2415988 (2025).","DOI":"10.1056\/NEJMoa2415988"},{"key":"1348_CR155","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","volume":"5","author":"F Fischbach","year":"2024","unstructured":"Fischbach, F. et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med 5, 550\u2013558.e2 (2024).","journal-title":"Med"},{"key":"1348_CR156","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1182\/blood-2024-194525","volume":"144","author":"F Mueller","year":"2024","unstructured":"Mueller, F. et al. Tolerability, efficacy, pharmacokinetics, and pharmacodynamics of BMS-986353 (CC-97540), a CD19-directed chimeric antigen receptor (CAR) T cell therapy manufactured using a next-generation process, for severe, refractory autoimmune diseases: updated data from ongoing phase 1, multicenter, open-label studies. Blood 144, 2088 (2024).","journal-title":"Blood"},{"key":"1348_CR157","doi-asserted-by":"publisher","first-page":"3469.1","DOI":"10.1182\/blood-2024-204169","volume":"144","author":"MR Seshadri","year":"2024","unstructured":"Seshadri, M. R. et al. A study of Kyv-101, a CD19 CAR T cell therapy, in participants with treatment refractory progressive multiple sclerosis. Blood 144, 3469.1 (2024).","journal-title":"Blood"},{"key":"1348_CR158","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2309439","volume":"390","author":"P Vermersch","year":"2024","unstructured":"Vermersch, P. et al. Inhibition of CD40L with frexalimab in multiple sclerosis. N. Engl. J. Med. 390, 589\u2013600 (2024).","journal-title":"N. Engl. J. Med."},{"issue":"(suppl.)","key":"1348_CR159","first-page":"24","volume":"31","author":"Y Xu","year":"2025","unstructured":"Xu, Y., Chen, X. & Tang, W. Positive phase 2 results of orelabrutinib in patients with relapsing\u2013remitting multiple sclerosis [abstract P094]. Mult. Scl. J. 31 (suppl.), 24\u2013244 (2025).","journal-title":"Mult. Scl. J."},{"key":"1348_CR160","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1207393","volume":"2016","author":"SJ Guzman","year":"2016","unstructured":"Guzman, S. J. & Gerevich, Z. P2Y Receptors in synaptic transmission and plasticity: therapeutic potential in cognitive dysfunction. Neural Plast. 2016, 1207393 (2016).","journal-title":"Neural Plast."},{"key":"1348_CR161","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1182\/blood-2024-204264","volume":"144","author":"PA Riedell","year":"2024","unstructured":"Riedell, P. A. et al. Rapcabtagene autoleucel (YTB323) in patients (pts) with relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL): phase II trial clinical update. Blood 144, 67 (2024).","journal-title":"Blood"},{"key":"1348_CR162","doi-asserted-by":"publisher","first-page":"1576020","DOI":"10.3389\/fnagi.2025.1576020","volume":"17","author":"Y-n Ma","year":"2025","unstructured":"Ma, Y. -n et al. The potential and challenges of TREM2-targeted therapy in Alzheimer\u2019s disease: insights from the INVOKE-2 study. Front. Aging Neurosci. 17, 1576020 (2025).","journal-title":"Front. Aging Neurosci."},{"key":"1348_CR163","unstructured":"Gregg, R. et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of VTX3232, a CNS-penetrant NRLP3 inhibitor, in participants with early-stage Parkinson\u2019s disease. In 2025 MDS Congress Abstract LBA-12 (2025)."},{"key":"1348_CR164","doi-asserted-by":"publisher","first-page":"14897","DOI":"10.1021\/acs.jmedchem.3c01398","volume":"66","author":"D Harrison","year":"2023","unstructured":"Harrison, D. et al. Discovery of clinical candidate NT-0796, a brain-penetrant and highly potent NLRP3 inflammasome inhibitor for neuroinflammatory disorders. J. Med. Chem. 66, 14897\u201314911 (2023).","journal-title":"J. Med. Chem."},{"key":"1348_CR165","first-page":"S78","volume":"40","author":"A Matta","year":"2025","unstructured":"Matta, A. et al. A randomized, double-blind, placebo-controlled, phase 2 study of the NLRP3 inhibitor Vent-02 in patients with mild to moderate Parkinson\u2019s disease [abstract]. 2025 International Congress of Parkinson\u2019s Disease and Movement Disorders. Mov. Disord. 40, S78\u2013S162 (2025).","journal-title":"Mov. Disord."},{"key":"1348_CR166","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1080\/21678421.2025.2515900","volume":"26","author":"A Yeole","year":"2025","unstructured":"Yeole, A. et al. A phase 2, proof-of-concept, placebo-controlled, randomized, multicenter, double-blind study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of Usnoflast (ZYIL1) in patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 26, 794\u2013801 (2025).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"1348_CR167","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139684","volume":"10","author":"A Maier","year":"2015","unstructured":"Maier, A. et al. Interleukin-1 antagonist anakinra in amyotrophic lateral sclerosis\u2014a pilot study. PLoS ONE 10, e0139684 (2015).","journal-title":"PLoS ONE"},{"key":"1348_CR168","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04795466 (2025)."},{"key":"1348_CR169","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cellimm.2018.09.001","volume":"339","author":"Z Omidian","year":"2019","unstructured":"Omidian, Z., Ahmed, R., Giwa, A., Donner, T. & Hamad, A. R. A. IL-17 and limits of success. Cell Immunol. 339, 33\u201340 (2019).","journal-title":"Cell Immunol."},{"key":"1348_CR170","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","volume":"30","author":"G Pagano","year":"2024","unstructured":"Pagano, G. et al. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease. Nat. Med. 30, 1096\u20131103 (2024).","journal-title":"Nat. Med."},{"key":"1348_CR171","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-040527","volume":"10","author":"JC Greenland","year":"2020","unstructured":"Greenland, J. C. et al. Azathioprine immunosuppression and disease modification in Parkinson\u2019s disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol. BMJ Open. 10, e040527 (2020).","journal-title":"BMJ Open."},{"key":"1348_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105315","volume":"80","author":"H Wiendl","year":"2023","unstructured":"Wiendl, H. et al. Phase 3 REMODEL I\/II trials: efficacy, safety, and tolerability of remibrutinib in patients with relapsing multiple sclerosis. Mult. Scler. Relat. Disord. 80, 105315 (2023).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1348_CR173","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1182\/blood-2021-150650","volume":"138","author":"Z Zhou","year":"2021","unstructured":"Zhou, Z. et al. Tri-specific CD19xCD20xCD22 VHH CAR-T cells (LCAR-AIO) eradicate antigen-heterogeneous B cell tumors, enhance expansion, and prolong persistence in preclinical in vivo models. Blood 138, 1700\u20131700 (2021).","journal-title":"Blood"},{"key":"1348_CR174","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06141486 (2026)."},{"key":"1348_CR175","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/study\/NCT06141473 (2026)."},{"key":"1348_CR176","unstructured":"Purves, D. et al. Neuroscience (Sinauer Associates, 2001)."},{"key":"1348_CR177","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.tins.2021.01.001","volume":"44","author":"N Plotegher","year":"2021","unstructured":"Plotegher, N., Filadi, R., Pizzo, P. & Duchen, M. R. Excitotoxicity revisited: mitochondria on the verge of a nervous breakdown. Trends Neurosci. 44, 342\u2013351 (2021).","journal-title":"Trends Neurosci."},{"key":"1348_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.conb.2022.102538","volume":"73","author":"NL Chanaday","year":"2022","unstructured":"Chanaday, N. L. & Kavalali, E. T. Role of the endoplasmic reticulum in synaptic transmission. Curr. Opin. Neurobiol. 73, 102538 (2022).","journal-title":"Curr. Opin. Neurobiol."},{"key":"1348_CR179","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3390\/ijms20092146","volume":"20","author":"R Fairless","year":"2019","unstructured":"Fairless, R., Williams, S. K. & Diem, R. Calcium-binding proteins as determinants of central nervous system neuronal vulnerability to disease. Int. J. Mol. Sci. 20, 2146 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"1348_CR180","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrn2379","volume":"9","author":"PS Pinheiro","year":"2008","unstructured":"Pinheiro, P. S. & Mulle, C. Presynaptic glutamate receptors: physiological functions and mechanisms of action. Nat. Rev. Neurosci. 9, 423\u2013436 (2008).","journal-title":"Nat. Rev. Neurosci."},{"key":"1348_CR181","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41586-025-08736-2","volume":"641","author":"F Miguez-Cabello","year":"2025","unstructured":"Miguez-Cabello, F. et al. GluA2-containing AMPA receptors form a continuum of Ca2+-permeable channels. Nature 641, 537\u2013544 (2025).","journal-title":"Nature"},{"key":"1348_CR182","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/35013064","volume":"405","author":"SQ Liu","year":"2000","unstructured":"Liu, S. Q. & Cull-Candy, S. G. Synaptic activity at calcium-permeable AMPA receptors induces a switch in receptor subtype. Nature 405, 454\u2013458 (2000).","journal-title":"Nature"},{"key":"1348_CR183","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40035-021-00278-7","volume":"11","author":"M Verma","year":"2022","unstructured":"Verma, M., Lizama, B. N. & Chu, C. T. Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration. Transl. Neurodegener. 11, 3 (2022).","journal-title":"Transl. Neurodegener."}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01348-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01348-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01348-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T12:02:43Z","timestamp":1787832163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01348-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":183,"alternative-id":["1348"],"URL":"https:\/\/doi.org\/10.1038\/s41577-026-01348-5","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"3 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.B. has received grants and\/or consultation funds from Biogen Idec, Bristol Meyer Squibbs, DFG, Hermann and Lilly-Schilling Foundation, Hexal, Merck Healthcare, Mylan, Novartis, Roche, Sanofi Genzyme and TEVA. F.Z. has recently received research grants and\/or consultation funds from Biogen, Ministry of Education and Research (BMBF), Bristol-Meyers-Squibb, Celgene, DFG, Janssen, Max-Planck-Society (MPG), Merck Serono, Novartis, Progressive MS Alliance (PMSA), Roche, Sanofi Genzyme, Sandoz and TEVA. J.S. and C.F.V. declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}